Monitor for additional insider selling in the next 30 days, while this cluster is within normal ranges, concentrated C-suite sales could signal caution ahead of earnings or regulatory decisions. The non-cash awards are standard compensation and not a concern.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $60.90entry
- T+1 · 9mo ago +0.94%α +1.39% · $61.47
- T+5 · 9mo ago −0.92%α +0.21% · $60.34
- T+20 · 8mo ago −9.16%α −2.76% · $55.32
- T+60 · 6mo ago −11.17%α −18.92% · $54.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two senior executives at BioMarin Pharmaceutical sold shares in the past week, with total open-market proceeds of approximately $1.98 million. The sales represent modest insider selling, while two other executives received non-cash stock awards. The selling activity is notable but not extreme relative to the company's $11.8B market cap.
Key Financial Metrics
Key Facts
- EVP and Chief Legal Officer George Eric Davis sold 26,061 shares for $1.60M in open-market transactions.
- EVP and Chief R&D Officer Gregory Friberg sold 6,326 shares for $381,937.
- Two other executives (Davis and CFO Brian Mueller) received non-cash stock awards totaling 12,860 shares with no monetary value exchanged.
- Total open-market selling value: $1.98 million (0.017% of $11.8B market cap).
- All transactions occurred within a 2-day window, indicating a clustered but routine insider activity period.
Financial Impact
$1.98 million in open-market sales by two C-suite executives; non-cash awards add no financial value.
Risk Factors
- Perception of insider pessimism if no offsetting buy activity follows.
- Potential for negative sentiment if selling continues ahead of key catalysts (e.g., FDA decisions).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-BMRN-1772156374596 |
Track record
16 reports on BMRN
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers